Published in Clin Exp Immunol on June 01, 1982
The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (1983) 1.18
The acute-phase response in (NZB X NZW)F1 and MRL/l MICE. J Exp Med (1982) 1.17
Objective monitoring of disease activity in polyarteritis by measurement of serum C reactive protein concentration. Br Med J (Clin Res Ed) (1984) 1.14
Clinical application of a new nephelometric technique to measure complement activation. J Clin Pathol (1983) 1.13
Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Ann Rheum Dis (1989) 1.02
Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal? J Clin Pathol (1989) 0.95
Evidence for B cell activation in patients with active rheumatoid arthritis. Clin Exp Immunol (1984) 0.91
C-reactive protein and serological indices of disease activity in systemic lupus erythematosus. Ann Rheum Dis (1983) 0.89
Comparative studies of serum and synovial fluid C reactive protein concentrations. Ann Rheum Dis (1987) 0.86
Comparison of serum and synovial fluid concentrations of beta 2-microglobulin and C reactive protein in relation to clinical disease activity and synovial inflammation in rheumatoid arthritis. Ann Rheum Dis (1989) 0.85
Proteomics in rheumatology: the dawn of a new era. F1000 Med Rep (2010) 0.81
Complement activation in neonatal infection. Arch Dis Child (1992) 0.81
Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open (2016) 0.78
Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Res Ther (2015) 0.78
Serum amyloid P component and autoimmune parameters in the assessment of arthritis activity in MRL/lpr/lpr mice. Clin Exp Immunol (1985) 0.77
Complement activation in uveitis. Br J Ophthalmol (1986) 0.76
Drug induced impairment of polymorphonuclear cell bactericidal ability in rheumatoid arthritis. Ann Rheum Dis (1987) 0.75
The role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritis. Genes Immun (2015) 0.75
C-reactive protein fifty years on. Lancet (1981) 5.93
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest (1975) 2.97
The assessment of disease activity in rheumatoid arthritis using a multivariate analysis. Rheumatol Rehabil (1981) 2.88
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest (1974) 2.81
Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta (1981) 2.77
The complement system in rheumatoid synovitis. I. An analysis of complement component activities in rheumatoid synovial fluids. Arthritis Rheum (1971) 2.53
Complement metabolism in rheumatoid arthritis. I. Longitudinal studies. Ann Rheum Dis (1973) 2.04
Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity. J Clin Invest (1977) 1.97
Analysis of immune complexes in synovial effusions of patients with rheumatoid arthritis. Clin Exp Immunol (1980) 1.89
Characterization of IgG complexes in patients with rheumatoid arthritis. Ann N Y Acad Sci (1975) 1.25
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med (1994) 8.10
Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol (1983) 7.47
Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol (1997) 7.27
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 6.10
C-reactive protein fifty years on. Lancet (1981) 5.93
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature (1997) 5.47
Neuropsychological effects of long-term exposure to organophosphates in sheep dip. Lancet (1995) 4.77
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. Eur Heart J (2001) 4.21
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med (1999) 3.88
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Trial comparing D-penicillamine and gold in rheumatoid arthritis. Preliminary report. Ann Rheum Dis (1974) 3.77
Anti-keratin antibodies in rheumatoid arthritis. Br Med J (1979) 3.33
Controlled trial of homoeopathic treatment of osteoarthritis. Lancet (1983) 3.30
Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med (1990) 3.17
Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest (1995) 3.14
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest (1993) 2.92
Role of complement in induction of the allergic response. Nat New Biol (1972) 2.90
The assessment of disease activity in rheumatoid arthritis using a multivariate analysis. Rheumatol Rehabil (1981) 2.88
Treatment of rheumatoid arthritis with fenoprofen: comparison with aspirin. Br Med J (1974) 2.84
Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta (1981) 2.77
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet (2001) 2.71
Activation of mouse complement by different classes of mouse antibody. Immunology (1979) 2.68
A test of the nature of cosmic acceleration using galaxy redshift distortions. Nature (2008) 2.65
The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure (1999) 2.64
Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care (2000) 2.63
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Effect of alcohol consumption on systemic markers of inflammation. Lancet (2001) 2.52
Serum amyloid P-component is an acute-phase reactant in the mouse. Nature (1979) 2.49
Complement dependence of localisation of aggregated IgG in germinal centres. Scand J Immunol (1975) 2.48
Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest (1982) 2.48
Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med (1974) 2.45
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease. Gastroenterology (1983) 2.37
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med (1982) 2.33
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum (1997) 2.31
Role of C3 in in vitro lymphocyte cooperation. Nature (1974) 2.27
Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem (1986) 2.25
C-reactive protein and coronary heart disease: a critical review. J Intern Med (2008) 2.25
Role of complement in the induction of immunological responses. Transplant Rev (1976) 2.21
Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. Nature (1978) 2.18
Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology (1997) 2.18
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med (1999) 2.17
Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods (1982) 2.15
Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet (1982) 2.10
Amyloidosis. Histopathology (1994) 2.10
Isolation of amyloid P component (protein AP) from normal serum as a calcium-dependent binding protein. Lancet (1977) 2.09
Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol (1979) 2.08
Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J (1982) 2.07
Structure of pentameric human serum amyloid P component. Nature (1994) 2.07
Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology (1979) 2.07
Phylogenetic aspects of C-reactive protein and related proteins. Ann N Y Acad Sci (1982) 2.03
Lhermitte-Duclos disease and Cowden disease: a single phakomatosis. Ann Neurol (1991) 2.01
Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med (2001) 1.99
Isolation of C-reactive protein by affinity chromatography. Clin Exp Immunol (1977) 1.97
Autoimmune hepatitis in childhood: a 20-year experience. Hepatology (1997) 1.97
C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM (2003) 1.93
Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. Proc Natl Acad Sci U S A (2005) 1.92
Histocompatibility antigens, autoantibodies, and immunoglobulins in alcoholic liver disease. Br Med J (1976) 1.91
Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J (1999) 1.87
Three dimensional structure of human C-reactive protein. Nat Struct Biol (1996) 1.87
Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A (1995) 1.83
C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation (2001) 1.81
Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med (1998) 1.78
A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation (1995) 1.77
Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. J Mol Biol (1997) 1.77
Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis (1980) 1.76
Adverse life events and breast cancer: case-control study. BMJ (1995) 1.74
Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int (1998) 1.71
Amyloid P component is located on elastic fibre microfibrils in normal human tissue. Nature (1981) 1.70
The protofilament substructure of amyloid fibrils. J Mol Biol (2000) 1.69
Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology (1982) 1.67
Indomethacin for soft-tissue injuries. A double-blind study in football players. Rheumatol Rehabil (1973) 1.67
Serum amyloid A protein and C-reactive protein levels in pulmonary tuberculosis: relationship to amyloidosis. Thorax (1984) 1.65
Biology of serum amyloid P component. Ann N Y Acad Sci (1982) 1.65
Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversion. J Am Coll Cardiol (2001) 1.63
Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet (1988) 1.61
C-reactive protein in SLE. Clin Rheum Dis (1982) 1.61
Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia (1988) 1.60
Clinical study comparing acupuncture, physiotherapy, injection and oral anti-inflammatory therapy in shoulder-cuff lesions. Curr Med Res Opin (1980) 1.60
Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology (2001) 1.59
Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J (2004) 1.59
Measurement of inflammation. II. Comparison of technetium clearance and thermography with standard methods in a clinical trial. Ann Rheum Dis (1973) 1.58
Amyloid P-component is a constituent of normal human glomerular basement membrane. J Exp Med (1980) 1.57